Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP
| Autor: | Ikuko Suzuki, Katsushi Tajima, Shuhei Okuyama, Hiroaki Kumagai, Masakazu Yamamoto, Eijiro Omoto, Kouji Saitou, Riko Tsumanuma, Shinji Satoh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research medicine.medical_specialty animal structures Multivariate analysis Comorbidity Gastroenterology Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Cyclophosphamide Aged Aged 80 and over Hematology Poor risk business.industry General Medicine Middle Aged medicine.disease Dose intensity Progression-Free Survival nervous system diseases Lymphoma Treatment Outcome 030104 developmental biology Oncology Doxorubicin Vincristine 030220 oncology & carcinogenesis Charlson comorbidity index Prednisone Female Lymphoma Large B-Cell Diffuse Rituximab business Diffuse large B-cell lymphoma psychological phenomena and processes |
| Zdroj: | Journal of Cancer Research and Clinical Oncology. 146:2995-3002 |
| ISSN: | 1432-1335 0171-5216 |
| DOI: | 10.1007/s00432-020-03279-7 |
| Popis: | Comorbidity and relative dose intensity (RDI) have been associated with survival in diffuse large B-cell lymphoma (DLBCL) patients, but both relationships remain unaddressed in the same patients. A retrospective review of consecutive DLBCL patients treated from January 2010 to October 2018 was performed. Data for the clinical characteristics of the patients, including the Charlson Comorbidity Index (CCI) and RDI, on their outcomes were evaluated. A total of 211 patients with a median age of 72 years (range 19–90 years) were analyzed. CCI ≥ 2 was associated with poor event-free survival (EFS) and overall survival (OS). RDI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink